HM15136 clinical trials

HM15136 (Efpegerglucagon) Treatment for 8 Weeks in Subjects Aged ≥2 Years With Congenital Hyperinsulinism (CHI)

This study looks at a new medicine called HM15136 for children and adults (aged 2 and over) with congenital hyperinsulinism (CHI). It aims to see if the medicine is safe, well-tolerated, and helps reduce low blood sugar when added to existing treatments.